LONDON -(Dow Jones)- A diabetes study by a U.S.-funded medical center, which highlighted a higher risk of death in patients receiving intensive blood glucose lowering treatment, has found no link between GlaxoSmithKline PLC’s (GSK) diabetes drug Avandia and the increased risk, the U.K. drugmaker said Wednesday.
